Skip to main content

Month: March 2022

Perma-Fix Reports Financial Results and Provides Business Update for 2021

Treatment Segment revenue increases 56.8% for the fourth quarter of 2021 Services Segment project backlog increases to approximately $66 million ATLANTA , March 31, 2022 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the fourth quarter and full year ended December 31, 2021. Mark Duff, President and CEO of the Company, commented, “Despite the challenges faced in 2021, we achieved a number of important milestones. Specifically, we were awarded strategic and high-profile projects within our Services Segment resulting in over $66 million in project backlog, which provides us a solid foundation for 2022 as these projects ramp up. We are encouraged by the approved federal budgets that will directly support our portfolio of Indefinite...

Continue reading

Trevena Reports Fourth Quarter and Full Year 2021 Results

— OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed new Chief Commercial Officer Topline data of OLINVYK vs IV morphine in high-risk subjects demonstrates statistically significant benefit in lowering respiratory depression $66.9M of cash at year end 2021 $40M OLINVYK ex-US royalty-based financing with R-Bridge Healthcare Fund— Company to host conference call today, March 31st, 2022, at 8:00 a.m. ET — CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview...

Continue reading

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended December 31, 2021. Recent HighlightsQuarter over quarter growth in KidneyIntelX testing volume Quarter over quarter growth in active physicians ordering KidneyIntelX KidneyIntelX now on-line with the Veterans Administration health system (VHA), New York physician led payor program CDPHP, Wake Forest Baptist Health and Atrium Health system Singing River Health System partnership to deploy KidneyIntelX informed care management to improve kidney health in individuals across the Mississippi...

Continue reading

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program New development program for ELX-02 for the treatment of Alport syndrome, a rare kidney genetic disorder; initiation of proof-of-concept clinical trial expected in second half of 2022 On track to start First in Human Phase 1 study in 2022 with ZKN-013 that is being developed for the treatment recessive dystrophic epidermolysis bullosa (RDEB) patients with nonsense mutations cells Treatment study of ZKN-013 in APCMin mouse model of familial adenomatous polyposis (FAP) demonstrates significant reductions of 40% in polyp count and 50% in polyp burden leading to improved...

Continue reading

Data Storage Corporation Reports 97% Increase in Revenue for the Fourth Quarter of 2021

Management to host conference call today, March 31, at 10:00 AM Eastern Time MELVILLE, N.Y., March 31, 2022 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity solutions for disaster-recovery, cloud infrastructure, cyber-security and data analytics solutions, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021. Chuck Piluso, CEO of Data Storage Corporation, commented, “I am pleased to report we achieved revenue growth of 97.1% and 59.6% for the fourth quarter and fiscal year 2021, respectively. We also achieved positive adjusted EBITDA for both the fourth quarter and full year. Importantly, we are successfully executing on our strategy to establish Data Storage as a leading provider of...

Continue reading

WarpSpeed Taxi Inc. (WRPT) SMART SHARING

$WRPT – WarpSpeed Taxi Inc. WarpSpeed Taxi Inc., a company involved in the development, testing, and marketing of a ride-hailing and food delivery computer and mobile device application known as “WarpSpeedTaxi”$WRPT – WarpSpeed Taxi Inc. WarpSpeedTaxi – The Perfect Solution$WRPT – WarpSpeed Taxi Inc. WarpSpeedTaxi – Ride Sharing$WRPT – WarpSpeed Taxi Inc. WarpSpeed Taxi AppLAS VEGAS, NV, March 31, 2022 (GLOBE NEWSWIRE) — WarpSpeed Taxi Inc. (OTC Pink: WRPT) (“WarpSpeed Taxi” or the “Company”), the developer of an all-in-one software solution for ride-hailing, food delivery, and courier services, is thrilled to present to you a new exciting service, WARPSPEED TAXI SMART SHARING. More and more drivers are quitting ride-sharing apps like Uber and Lyft due to the recent surge in...

Continue reading

Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias (AML) at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference:Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference    • Panel: Attacking AML: New Approaches       Date: Thursday, April 14, 2022  Time: 1:30 – 2:30 PM ET   Format: Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst   Webcast: LinkThe audio...

Continue reading

Acerus Announces Amendments to Loan Facility

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced that it has entered into an amending agreement with First Generation Capital Inc. (“First Generation”), a company affiliated with the Chairman of the Board of Directors of Acerus1, to increase its existing secured loan facility (the “Loan Facility”) from US$30.845 million to US$35.845 million. This increase will be made available to the Company by way of one or more advances under a secured grid promissory note with First Generation provided that any such advance will be made before April 30, 2022. The Loan Facility bears interest at a rate of eight percent (8%) per annum and is repayable in full on December 31, 2024 but can be prepaid in full or in part without penalty. The proceeds from...

Continue reading

Base Carbon Provides Cookstove Project Update and Reports Year-End 2021 Financial Results

TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Base Carbon Inc. (NEO:BCBN) (including its subsidiaries, “Base Carbon”, or the “Company”) is pleased to provide an update on its Rwanda cookstove project (the “Rwanda Cookstove Project”) which is an expansion of an existing, registered, carbon reduction project under the DelAgua Group as the Coordinating/Managing Entity. Base Carbon is also pleased to announce financial results for the year ended December 31, 2021. All financial references are denominated in US dollars, unless otherwise noted. Rwanda Cookstove Project Update As previously announced, Base Carbon has entered into a carbon reduction project agreement with a subsidiary of the DelAgua Group to supply cookstoves in the country of Rwanda as part of an expansion of an existing Verra-registered carbon reduction project. As of March 17,...

Continue reading

Minim Reports Revenue Growth of 16% for Full-Year 2021

Company announces its innovative software roadmap and new position as the #1 cable modem and gateway seller on Amazon, the leading e-commerce channel for the category, since December 2021 MANCHESTER, NH, March 31, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Minim, Inc. (NASDAQ: MINM), the creator of intelligent networking products, today reported fourth quarter and full year financial results for the periods ended December 31, 2021. Full-year 2021 Financial Highlights:Net revenue of $55.4 million, a 16% increase over 2020, as the industry experienced an estimated 10% decrease in modem and modem/router sales.1 Total deferred revenue as of December 31, 2021 was $736 thousand, a 100% increase from the previous year. Gross margin of 31.6% compared to 28.4% in 2020, an improvement of 328 basis points. Net loss of $3.6 million,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.